Current Issue
VOL 14 NO 6 • Sep/Oct 2023
This issue’s cover illustration depicts a cross section of the pancreas with nodules in the head and a dilated duct in the tail of the pancreas with an overlay of a family history that would lead to an increased risk of pancreatic ductal adenocarcinoma. Pancreatic ductal adenocarcinoma develops in the exocrine regions of the pancreas, commonly in the head, and is usually symptomatic in the early stages. Because of the lack of symptoms and limited screening outcomes, pancreatic cancer is often detected at later stages resulting in poorer outcomes. Artwork by Alexandra Webber © 2023, DNA Illustrations, Inc., Asheville, North Carolina.EditorialBeth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPOInnovative clinical trials identify appropriate endpoints when seeking to evaluate potential new cancer treatments, better ways of using existing medications, or enhanced supportive care techniques. A recent X (formerly Twitter) post highlighted a workshop held in July 2023 sponsored by the FDA, ...
EditorialMary Heery, APRN, AOCNS®, CBCNTamoxifen and aromatase inhibitors are widely prescribed therapies for the treatment of breast cancer. Tamoxifen is a selective estrogen receptor modulator that treats hormone-sensitive breast cancers. Research has demonstrated that tamoxifen therapy improves survival and reduces the risk of deve...
Research and ScholarshipJessica Tamar Davis, DNP, AOCNP®, ACHPNOncology care has experienced a shift over the past decade, becoming more focused on providing goal-concordant care for seriously ill patients. The need for effective communication and clear treatment plans to match patients’ values and goals has become essential (Sanders et al., 2018). Researche...
Research and Scholarship Rakesh Popat,(1) BSc, MBBS, MRCP, FRCPath, PhD, Sagar Lonial,(2) MD, FACP, Peter M. Voorhees,(3) MD, Simona Degli Esposti,(4) MD, Boris Gorsh,5a PharmD, Ira Gupta,(5a) MD, Joanna Opalinska,(5) PhD, Sandhya Sapra,(5) PhD, Trisha Piontek,(5) BS, RN, Zangdong He,(5) PhD, David Kleinman,(6) MD, MBA, Debra Schaumberg,(7) SCD, OD, MPH, Antoine Regnault,(8) PhD, Juliette Meunier,(8) MSc, and Laurie Eliason,(5a) MPHMultiple myeloma (MM) is a relapsing, incurable hematologic cancer that eventually becomes refractory to treatments. Therapies to treat relapsed/refractory MM (RRMM) aim to control disease progression, prolong survival, reduce disease-related symptoms, and optimize health-related quality of life ...
Review ArticleEkaterina Kachur, PharmD, BCOP, Jai N. Patel, PharmD, BCOP, CPP, Allison L. Morse, PharmD, BCOP, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, and Justin R. Arnall, PharmD, BCOPSince its first US Food and Drug Administration (FDA) approval in 1959, cyclophosphamide use has expanded to solid and hematologic malignancies, autoimmune diseases, and mobilization and conditioning regimens for hematopoietic cell transplantation (HCT). More recently, cyclophosphamide has emerge...
Review ArticleTracy Lowe,(1) PhD, MS, RN, Jane DeLuca,1 PhD, MS, RN, CPNP-PC, Ludovico Abenavoli,(2) MD, PhD, MSc, and Luigi Boccuto,(1) MDPancreatic cancer is one of the deadliest cancers in the United States, accounting for 8% of cancer deaths each year. It is surpassed only by lung cancer (23%) and colorectal cancer (9%) in terms of causes of cancer deaths annually (Centers for Disease Control and Prevention [CDC], 2022). Pancrea...
Grand RoundsHeather Townsend, MPAP, PA-CCase Study
SY is an 86-year-old female who presented to the emergency department with an initial complaint of dizziness, fatigue, and generalized weakness over the past several days. Past medical history is significant for hyperlipidemia and esophagitis with esophageal structuring. Previous surgi...
Diagnostic SnapshotSarah Hemstetter, MSN, CRNP, AOCNP®History and Chief Complaint
KS is a 52-year-old female with a history of chronic kidney disease, hypertension, and relapsed IgG kappa multiple myeloma who is postautologous stem cell transplant and receiving therapy with daratumumab (Darzalex), lenalidomide, dexamethasone, and denosumab. KS prese...
